Successful Phase II Clinical Results for COVID-19 Treatment

Please login or
register
18.01.2021
symbolic picture corona care

Swiss Pharmacan announced the full results of Phase II double-blind, placebo-controlled clinical trial for its anti-inflammatory treatment ArtemiC on persons diagnosed with COVID-19. ArtemiC met all the Phase II primary and secondary endpoints and demonstrated to improve the clinical recovery of COVID-19 patients.

The results of the clinical trial on ArtemiC involving 50 patients show that the treatment statistically significantly improved the clinical recovery of COVID-19 patients in comparison with the Placebo Group. The results deliver a full safety and efficacy profile, demonstrating to improve and expedite the clinical recovery in moderate COVID-19 patients, with no drug-related adverse events. None of the patients supported by ArtemiC required additional oxygen, mechanical ventilation or intensive care, compared to 23.4% in the placebo group requiring further assistance. The trial was completed on 50 COVID-19 infected patients across 3 independent hospital sites in Israel and met all the FDA requirements for a COVID-19 study.

These results now open potential market opportunities for ArtemiC to a wide range of diseases related to cytokine storm such as influenza, autoimmune diseases, inflammatory GI diseases and chemotherapy patients. Following the successful Phase II results, a Phase III clinical trial is planned for the first half of 2021. The Phase III trial is anticipated to be an international multicentre study to encompass a wide range of inflammatory indications for the use of ArtemiC as a treatment.

Swiss Pharmacan has partnered with the Australian MGC Pharma for the clinical trial. US-based Relay Medical has acquired the exclusive North American rights for the manufacturing and sales of several products of Swiss Pharmacan.

(Press release / SK)

0Comments

More news about

Swiss PharmaCan

rss